Document is current

Article History

Received: 23 July 2024

Revised: 23 July 2024

Accepted: 3 October 2024

First Online: 21 October 2024

Competing interests

: AB received reimbursement for attending symposia from Gilead. AFH received reimbursement for attending symposia from Daiichi Sankyo. ASK received institutional grants from Roche and Pfizer; and received compensation as a member of the scientific advisory board from Novartis, Astra Zeneca, MDS, Roche and Eli Lilly Danmark A/S (all outside the submitted work). TB received reimbursement for attending symposia from Daiichi Sankyo; received institutional grants from Pfizer, Astra Zeneca, Novartis, Samsung Bioepis, Seattle Genetics, Merck, Eli Lilly, and Daiichi Sankyo; and received compensation as a member of the scientific advisory board from Novartis (outside the submitted work). UL received institutional grants from Pfizer, Eli Lilly, BMS, GSK, Incyte, and Roche; and received compensation as a member of the scientific advisory board from Bayer, Novartis and Pfizer (all outside the submitted work). IT and TSP declare no potential competing interests.

: The study was approved by The Research Ethics Committee Secretary in the Capital Region (approval number R-22033077) and filed to the Danish Data Protection Agency (approval number P-2022-287). The study was conducted by a multidisciplinary team comprising specialists in clinical oncology, clinical pharmacology, and public health. We followed the ESMO Guidance for Reporting Oncology real-World evidence (GROW) [].